Immunovant, Inc. (NASDAQ: IMVT) Q4 2024 Earnings Call | 5/29/2025

About this video

Immunovant, Inc. (NASDAQ: IMVT) reported its Q4 2024 results on May 29, 2025, posting a net loss of $106.4 million, or $0.64 per share—narrower than analyst expectations and better than the estimated loss of $0.73 per share. While losses widened year-over-year, the company’s strong cash position of $714 million provides a financial runway through 2027, supporting its ambitious clinical development plans. Research and development expenses rose 42% to $93.7 million, reflecting accelerated clinical trial activity for lead asset IMVT-1402, which is now being advanced in six autoimmune indications. General and administrative expenses also increased to $20.2 million, driven by higher personnel and professional fees. Immunovant’s pipeline saw significant progress, with positive results from batoclimab trials in myasthenia gravis and CIDP, and the company is on track to initiate up to 10 studies with IMVT-1402 by March 2026. Leadership changes include the appointment of Eric Venker as CEO and Tiago Girao as CFO, signaling a strategic shift toward late-stage development and maximizing pipeline value. Although Immunovant has no approved products yet and thus no revenue, its broad clinical strategy and robust cash reserves position it well for upcoming data readouts and potential market opportunities. About Inside Ticker: For more expert analysis and real-time updates on Immunovant, Inc. (NASDAQ: IMVT) and other market movers, follow Inside Ticker and visit InsideTicker.com for in-depth reports, financial insights, and the latest news on leading companies. #Immunovant #IMVT #EarningsCall #Q42024 #Biotech #Autoimmune #ClinicalTrials #StockMarket #Investing #InsideTicker